Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Archive for August, 2012

Discovery Laboratories: The Street Is Getting on Board With Me

My Recent History on Discovery Laboratories On February 22, 2012, I initiated coverage of Discover Laboratories with a Buy and at a price of $2.82; the report was called Surfaxin Should Be Approved on its March 6th PDUFA Date. I urged investors to buy the stock before the PDUFA date. When I issued the report, […]

Cadence Strengthens on Positive News Flow

Recent Positive News Cadence’s stock has strengthened recently on the basis of two new pieces of information. The first deals with market research numbers from Wolters Kluwer; its estimates for vials shipped in July indicate Ofirmev is on track to meet management guidance for a sequential quarterly increase of 23% to 28% in 3Q, 2012 […]

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

  I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report called “Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections” which was issued on May 30, 2012 when Trius closed at a price of $5.01. I laid out my thinking on why I thought […]

An Update on Trius Therapeutics’ Tedizolid; a Potential Blockbuster for Treating MRSA Infections (TSRX, $5.41)

Investment Recommendation I am reiterating my buy recommendation on Trius Therapeutics (NASDAQ: TSRX). This note is follow-up to a 35 page report called “Trius Therapeutics’ Tedizolid has Blockbuster Potential for MRSA Infections” which was issued on May 30, 2012 when Trius closed at a price of $5.01. I laid out my thinking on why I […]

Manish Singh Resigns as CEO of ImmunoCellular Therapeutics: Implications for Northwest Biotherapeutics and ImmunoCellular

ImmunoCellular (IMUC.OB) has issued a press release stating that Manish Singh has resigned as CEO. He will be succeeded in the interim by Dr. John Yu, a founder of the company. The reasons for the resignation were not explained, but there may be some relationship to recent activity on the part of bloggers questioning the […]

Johnson & Johnson: A Core Holding for the Long Haul

  I have just written a report on JNJ in which I reiterated my Buy recommendation. I don’t see a vibrant world economy in the next few years that will reduce pressure on healthcare spending and I think that JNJ will probably show growth in operational sales and earnings for in-line businesses in the 3% […]

Cadence Pharmaceuticals Ofirmev Has Gained Traction Producing Upside Surprise in 2Q, 2012

I reiterate my Buy recommendation on Cadence. The Ofirmev launch has now gained traction as just reported 2Q, 2012 revenues of $11.1 million exceeded guidance of $10.0 to $10.4 million. Management guidance for 3Q, 2012 of $13.7 to $14.2 million is better than the existing Street consensus of $13.6 million. The metrics for gauging the […]

Price Drop Following Side Effect Issue with Hepatitis C Pipeline Drug Creates Buying Opportunity

Bristol-Myers disclosed on August 1, 2012 that it has suspended a phase II trial in hepatitis C in which BMS-986094, its nucleotide polymerase inhibitor, was being studied in combination with daclatasvir, its NS5a inhibitor. BMS-986094 has been broadly viewed as the cornerstone of BMY’s effort to develop an all oral combination treatment for hepatitis C […]

Johnson & Johnson: A Buy and Core Holding for the Long Haul (JNJ, $68.35)

Investment Overview Johnson & Johnson (JNJ) is a colossus among health care companies with an estimated $68 billion of revenues in 2012 and a current market capitalization of $188 billion. Its sales are divided into three major business categories: Pharmaceuticals (38%), Medical Devices and Diagnostics or MD&D (41%) and Consumer (21%). It is the largest […]

Cadence Pharmaceuticals’ Ofirmev Launch is Gaining Traction (CADX, $4.02)

Investment Background Cadence Pharmaceuticals (CADX) achieved the goal of every emerging bio-pharmaceutical company when it received US approval for its first product Ofirmev on November 2, 2010; it was then launched on January 17, 2011. Ofirmev is an intravenous formulation of acetaminophen that was licensed from Bristol-Myers Squibb (BMY). It has been marketed in Europe […]